Literature DB >> 16649160

Design, synthesis, and calcium channel antagonist activity of new 1,4-dihydropyridines containing 4-(5)-chloro-2-ethyl-5-(4)-imidazolyl substituent.

Asghar Davood1, Niloufar Mansouri, Ahmad Rerza Dehpour, Hamed Shafaroudi, Eskandar Alipour, Abbas Shafiee.   

Abstract

A series of dialkyl, dicycloalkyl, and diaryl ester analogues of nifedipine, in which the ortho-nitro phenyl group at position 4 is replaced by the 4-(5)-chloro-2-ethyl-5-(4)-imidazolyl substituent, were synthesized and evaluated as calcium channel antagonists using the high K+ contraction of guinea pig ileal longitudinal smooth muscle. The results for the symmetrical ester series showed that increasing the length of the chain in C3- and C5-ester substituents increased the activity and the most active compound was the diphenylethyl ester derivative, so it was more active than the reference drug nifedipine. In unsymmetrical diester series, when R1 is methyl or ethyl, increasing lipophilic properties in the R substituent, increased the activity. The most active compounds were methyl/phenethyl and ethyl/phenethyl ester derivatives, being slightly more active than nifedipine.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16649160     DOI: 10.1002/ardp.200600013

Source DB:  PubMed          Journal:  Arch Pharm (Weinheim)        ISSN: 0365-6233            Impact factor:   3.751


  6 in total

1.  The transient receptor potential channel antagonist SKF96365 is a potent blocker of low-voltage-activated T-type calcium channels.

Authors:  A Singh; M E Hildebrand; E Garcia; T P Snutch
Journal:  Br J Pharmacol       Date:  2010-07       Impact factor: 8.739

2.  Design of Small Molecules with HIV Fusion Inhibitory Property Based on Gp41 Interaction Assay.

Authors:  Soroush Sardari; Kayhan Azadmanesh; Fereidoun Mahboudi; Asghar Davood; Ruhollah Vahabpour; Rezvan Zabihollahi; Hosna Gomari
Journal:  Avicenna J Med Biotechnol       Date:  2013-04

3.  Assessment of the Cytotoxic Effect of a Series of 1,4-Dihydropyridine Derivatives Against Human Cancer Cells.

Authors:  Nima Razzaghi-Asl; Ramin Miri; Omidreza Firuzi
Journal:  Iran J Pharm Res       Date:  2016       Impact factor: 1.696

4.  Anticonvulsant Effects of New 1, 4-DihydropyridineDerivatives Containing Imidazolyl Moiety Against Seizures Induced by Pentylenetetrazole and Maximal Electroshock in Mice.

Authors:  Yasaman Rasouli; Asghar Davood; Armin Alaee; Golnoush Dehqani; Hamed Shafaroudi; Mahboubeh Lotfinia; Mohsen Amini; Abbas Shafiee
Journal:  Iran J Pharm Res       Date:  2017       Impact factor: 1.696

5.  Design, Synthesis and Anti-Tubercular Activity of Novel 1, 4-Dihydropyrine-3, 5-Dicarboxamide Containing 4(5)-Chloro-2-Ethyl- 5(4)-Imidazolyl Moiety.

Authors:  Maryam Iman; Asghar Davood; Mahboubeh Lotfinia; Golnoush Dehqani; Soroush Sardari; Parisa Azerang; Mohsen Amini
Journal:  Iran J Pharm Res       Date:  2016       Impact factor: 1.696

6.  Design, Synthesis and Evaluation of Antitubercular Activity of Novel Dihydropyridine Containing Imidazolyl Substituent.

Authors:  Maryam Iman; Asghar Davood; Golnoush Dehqani; Mahboubeh Lotfinia; Soroush Sardari; Parisa Azerang; Mohsen Amini
Journal:  Iran J Pharm Res       Date:  2015       Impact factor: 1.696

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.